{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:07:33Z","timestamp":1769576853555,"version":"3.49.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T00:00:00Z","timestamp":1500336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T00:00:00Z","timestamp":1500336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Sciences","doi-asserted-by":"crossref","award":["16H06241"],"award-info":[{"award-number":["16H06241"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007786","name":"National Center for Child Health and Development","doi-asserted-by":"publisher","award":["26-5"],"award-info":[{"award-number":["26-5"]}],"id":[{"id":"10.13039\/100007786","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Natural Sciences Foundation","award":["81202225"],"award-info":[{"award-number":["81202225"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2592-5","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T12:53:45Z","timestamp":1500382425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China"],"prefix":"10.1186","volume":"17","author":[{"given":"Xiuting","family":"Mo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyan","family":"Gai Tobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiwen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rintaro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,18]]},"reference":[{"key":"2592_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","volume":"7","author":"S de Sanjose","year":"2007","unstructured":"de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7:453\u20139.","journal-title":"Lancet Infect Dis"},{"key":"2592_CR2","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1038\/sj.bjc.6601813","volume":"90","author":"L Yang","year":"2004","unstructured":"Yang L, Parkin DM, Li LD, Chen YD, Bray F. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer. 2004;90:2157\u201366.","journal-title":"Br J Cancer"},{"key":"2592_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/ijc.26042","volume":"130","author":"JF Shi","year":"2012","unstructured":"Shi JF, Canfell K, Lew JB, Qiao YL. The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer. 2012;130:641\u201352.","journal-title":"Int J Cancer"},{"key":"2592_CR4","doi-asserted-by":"publisher","first-page":"6258","DOI":"10.1016\/j.vaccine.2008.09.036","volume":"26","author":"W Techakehakij","year":"2008","unstructured":"Techakehakij W, Feldman RD. Cost-effectiveness of HPV vaccination compared with pap smear screening on a national scale: a literature review. Vaccine. 2008;26:6258\u201365.","journal-title":"Vaccine"},{"key":"2592_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1750-9378-7-38","volume":"7","author":"B Serrano","year":"2012","unstructured":"Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agents Cancer. 2012;7:38.","journal-title":"Infect Agents Cancer"},{"key":"2592_CR6","unstructured":"Chitnis D. Data on two-dose 9-valent HPV vaccinations encouraging, but more needed. \n                    https:\/\/www.pm360online.com\/data-on-two-dose-9-valenthpv-vaccinations-encouraging-but-more-needed\/\n                    \n                  . Cited date: 24 Feb 2016."},{"key":"2592_CR7","unstructured":"Liu W. China approves GSK's HPV vaccine. \n                    http:\/\/www.chinadaily.com.cn\/china\/2016-07\/18\/content_26131226.htm\n                    \n                  . Cited date: 18 July 2016."},{"key":"2592_CR8","unstructured":"GSK. GSK announces Cervarix\u2122 approved in China to help protect women from cervical cancer. \n                    http:\/\/www.gsk-china.com\/en-gb\/media\/press-releases\/2016\/gsk-announces-cervarix-approved-in-china-to-help-protect-women-from-cervical-cancer\/\n                    \n                  . Cited date: 18 July 2016."},{"key":"2592_CR9","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/ijc.24116","volume":"124","author":"H De Vuyst","year":"2009","unstructured":"De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124:1626\u201336.","journal-title":"Int J Cancer"},{"key":"2592_CR10","unstructured":"Merck & CO. I. Highlights of prescribing information: GARDASIL\u00ae [Human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant]. \n                    https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm426457.pdf\n                    \n                  . Cited date: 28 Dec 2014."},{"key":"2592_CR11","unstructured":"Merck & CO. I. Highlights of prescribing information: GARDASIL\u00ae9 (Human papillomavirus 9-valent vaccine, recombinant). \n                    www.merck.com\/product\/patent\/home.html\n                    \n                  . Cited date: 12 Mar 2015."},{"key":"2592_CR12","unstructured":"World Health Organization. Cervical cancer screening in developing countries: report of a WHO consultation. World Health Organization; 2002."},{"key":"2592_CR13","volume-title":"Chinese cancer screening and early detection and early treated guidelines (trail)","author":"Z Dong","year":"2005","unstructured":"Dong Z. Chinese cancer screening and early detection and early treated guidelines (trail). Beijing: Peking University Medical Press; 2005."},{"key":"2592_CR14","first-page":"358","volume":"374","author":"Editorial","year":"2009","unstructured":"Editorial. Women's health in rural China. Lancet. 2009;374:358.","journal-title":"Lancet"},{"key":"2592_CR15","unstructured":"Meng R, Ma W, Xu Y, Song X, Nie S, Xu H, et al. Screening rates of cervical cancer, breast cancer and their influential factors in Guangdong Province. South China J Pre Med. 2010:8\u201310."},{"key":"2592_CR16","first-page":"542","volume":"24","author":"JM Li","year":"2008","unstructured":"Li JM, Liu ZY, Ji HW, Fan YH, Wang W. Status of screening and KAP of cervical cancer in a community of Shenzhen. Chin J Health Educ. 2008;24:542\u20134.","journal-title":"Chin J Health Educ"},{"key":"2592_CR17","unstructured":"Liu HR. Cervical cancer screening rates of its influential factors. World of mother and infant. 2015;"},{"key":"2592_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-2026-y","volume":"16","author":"Y-J Liu","year":"2016","unstructured":"Liu Y-J, Zhang Q, Hu S-Y, Zhao F-H. Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China. BMC Cancer. 2016;16:1\u201311.","journal-title":"BMC Cancer"},{"key":"2592_CR19","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1186\/s12885-016-2893-x","volume":"16","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Liu Y-J, Hu S-Y, Zhao F-H. Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16\/18 vaccine in China. BMC Cancer. 2016;16:848.","journal-title":"BMC Cancer"},{"key":"2592_CR20","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1016\/j.vaccine.2015.02.052","volume":"33","author":"CE Levin","year":"2015","unstructured":"Levin CE, Sharma M, Olson Z, Verguet S, Shi J-F, Wang S-M, et al. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China. Vaccine. 2015;33:2830\u201341.","journal-title":"Vaccine"},{"key":"2592_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1472-6963-10-11","volume":"10","author":"PH Liu","year":"2010","unstructured":"Liu PH, Hu FC, Lee PI, Chow SN, Huang CW, Wang JD. Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan. BMC Health Serv Res. 2010;10:11.","journal-title":"BMC Health Serv Res"},{"key":"2592_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3201\/eid1301.060438","volume":"13","author":"EH Elbasha","year":"2007","unstructured":"Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28\u201341.","journal-title":"Emerg Infect Dis"},{"key":"2592_CR23","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/oxfordjournals.aje.a010166","volume":"151","author":"ER Myers","year":"2000","unstructured":"Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151:1158\u201371.","journal-title":"Am J Epidemiol"},{"key":"2592_CR24","volume-title":"Technical proposal for screening and early detection and treatment of cancer in China. People's medical publishing house","author":"W Longde","year":"2009","unstructured":"Longde W, Yu P. Technical proposal for screening and early detection and treatment of cancer in China. People's medical publishing house; 2009."},{"key":"2592_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/1472-6963-12-123","volume":"12","author":"JF Shi","year":"2012","unstructured":"Shi JF, Chen JF, Canfell K, Feng XX, Ma JF, Zhang YZ, et al. Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study. BMC Health Serv Res. 2012;12:123.","journal-title":"BMC Health Serv Res"},{"key":"2592_CR26","first-page":"87","volume":"30","author":"JF Shi","year":"2009","unstructured":"Shi JF, Xiang W, Qiao YL. A review of health economic evaluation on cervical cancer screening by visual inspection with acetic acid. Zhonghua Liu Xing Bing Xue Za Zhi. 2009;30:87\u201390.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"2592_CR27","doi-asserted-by":"crossref","unstructured":"Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290(6):781\u20139.","DOI":"10.1001\/jama.290.6.781"},{"key":"2592_CR28","volume-title":"Cost-effectiveness on various modalities of cervical cancer screening in rural China: Chinese academy of medical sciences & Peking union medical college","author":"S Jufang","year":"2009","unstructured":"Jufang S. Cost-effectiveness on various modalities of cervical cancer screening in rural China: Chinese academy of medical sciences & Peking union medical college; 2009."},{"key":"2592_CR29","unstructured":"GlaxoSmithKline. Highlights of prescribing information: CERVARIX [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant]. \n                    http:\/\/us.gsk.com\/products\/assets\/us_cervarix.pdf\n                    \n                  . Cited date: 28 Dec 2014."},{"key":"2592_CR30","volume-title":"An epidemic study on HPV distribution in genital warts, invasive cervical cancer in China: Chinese academy of medical sciences & Peking union medical college","author":"C Wen","year":"2010","unstructured":"Wen C. An epidemic study on HPV distribution in genital warts, invasive cervical cancer in China: Chinese academy of medical sciences & Peking union medical college; 2010."},{"key":"2592_CR31","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","volume":"25","author":"SE Olsson","year":"2007","unstructured":"Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931\u20139.","journal-title":"Vaccine"},{"key":"2592_CR32","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/S1470-2045(10)70256-4","volume":"11","author":"FH Zhao","year":"2010","unstructured":"Zhao FH, Lin MJ, Feng C, Hu SY, Rong Z, Belinson JL, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010;11:1160\u201371.","journal-title":"Lancet Oncol"},{"key":"2592_CR33","volume-title":"Health economic evaluation and economic feasibility research of cervical cancer screening in rural areas: medical school of Dalian","author":"L Dongyan","year":"2010","unstructured":"Dongyan L. Health economic evaluation and economic feasibility research of cervical cancer screening in rural areas: medical school of Dalian; 2010."},{"key":"2592_CR34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.5732\/cjc.014.10125","volume":"33","author":"ZM Zhao","year":"2014","unstructured":"Zhao ZM, Pan XF, Lv SH, Xie Y, Zhang SK, Qiao YL, et al. Quality of life in women with cervical precursor lesions and cancer: a prospective, 6-month, hospital-based study in China. Chin J Cancer. 2014;33:339\u201345.","journal-title":"Chin J Cancer"},{"key":"2592_CR35","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s005200050011","volume":"8","author":"A Molassiotis","year":"2000","unstructured":"Molassiotis A, Chan CW, Yam BM, Chan SJ. Quality of life in Chinese women with gynaecological cancers. Support Care Cancer. 2000;8:414\u201322.","journal-title":"Support Care Cancer"},{"key":"2592_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2458-12-153","volume":"12","author":"JF Shi","year":"2012","unstructured":"Shi JF, Kang DJ, Qi SZ, Wu HY, Liu YC, Sun LJ, et al. Impact of genital warts on health related quality of life in men and women in mainland China: a multicenter hospital-based cross-sectional study. BMC Public Health. 2012;12:153.","journal-title":"BMC Public Health"},{"key":"2592_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-14-1","volume":"14","author":"SZ Qi","year":"2014","unstructured":"Qi SZ, Wang SM, Shi JF, Wang QQ, Chen XS, Sun LJ, et al. Human papillomavirus-related psychosocial impact of patients with genital warts in China: a hospital-based cross-sectional study. BMC Public Health. 2014;14:1\u20138.","journal-title":"BMC Public Health"},{"key":"2592_CR38","unstructured":"People Daily. What is HPV? \n                    http:\/\/weibo.com\/rmrb?is_hot=1\n                    \n                  . Cited date: 11 Mar 2016."},{"key":"2592_CR39","unstructured":"Medscape. HPV 9: The Latest ACIP Guidance. \n                    http:\/\/www.medscape.com\/viewarticle\/841676\n                    \n                  . Cited date: 23 Mar 2015."},{"key":"2592_CR40","unstructured":"Chinses anti-cancer association. Early screen of cervical cancer [in Chinese] \n                    http:\/\/www.caca.org.cn\/system\/2008\/07\/31\/010009930.shtml\n                    \n                  . Cited date: 15 Dec 2008."},{"key":"2592_CR41","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology \n                    http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp\n                    \n                  . 2013."},{"key":"2592_CR42","volume-title":"Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health","author":"World Health Organization","year":"2001","unstructured":"World Health Organization. Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva: WHO; 2001."},{"key":"2592_CR43","unstructured":"National Bureau of Statistics of China. Gross Domestic Product \n                    http:\/\/data.stats.gov.cn\/ks.htm?cn=C01&zb=A0501\n                    \n                  . Cited date: 1 Dec 2015."},{"key":"2592_CR44","volume-title":"Disease Prevnetion and Control Bureau, MOH. Chinese Cancer Registry Annual Report (2011)","author":"National Office for Cancer Prevention and Control NCfCR","year":"2011","unstructured":"National Office for Cancer Prevention and Control NCfCR. Disease Prevnetion and Control Bureau, MOH. Chinese Cancer Registry Annual Report (2011). Beijing: Military Medical Science Press; 2011."},{"key":"2592_CR45","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1001\/jama.287.18.2372","volume":"287","author":"JS Mandelblatt","year":"2002","unstructured":"Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002;287:2372\u201381.","journal-title":"JAMA"},{"key":"2592_CR46","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/j.1365-2753.2010.01453.x","volume":"17","author":"MK Chen","year":"2011","unstructured":"Chen MK, Hung HF, Duffy S, Yen AM, Chen HH. Cost-effectiveness analysis for pap smear screening and human papillomavirus DNA testing and vaccination. J Eval Clin Pract. 2011;17:1050\u20138.","journal-title":"J Eval Clin Pract"},{"issue":"Suppl 5","key":"2592_CR47","doi-asserted-by":"publisher","first-page":"F192","DOI":"10.1016\/j.vaccine.2012.06.075","volume":"30","author":"MA Kane","year":"2012","unstructured":"Kane MA, Serrano B, de Sanjose S, Wittet S. Implementation of human papillomavirus immunization in the developing world. Vaccine. 2012;30(Suppl 5):F192\u2013200.","journal-title":"Vaccine"},{"key":"2592_CR48","doi-asserted-by":"crossref","unstructured":"Chesson HW, Markowitz LE, Hariri S, Ekwueme DU, Saraiya M. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: estimates from a simplified transmission model. Human vaccines & immunotherapeutics. 2016:1\u201310.","DOI":"10.1080\/21645515.2016.1140288"},{"key":"2592_CR49","doi-asserted-by":"crossref","unstructured":"Brisson M, Laprise JF, Chesson HW, Drolet M, Malagon T, Boily MC, et al. Health and economic impact of switching from a 4-Valent to a 9-Valent HPV vaccination program in the United States. J Natl Cancer Inst. 2016;108","DOI":"10.1093\/jnci\/djv282"},{"key":"2592_CR50","doi-asserted-by":"publisher","first-page":"e48426","DOI":"10.1371\/journal.pone.0048426","volume":"7","author":"K Sorapop","year":"2012","unstructured":"Sorapop K, Nicole Gastineau C, Kim JJ. Potential benefits of second-generation human papillomavirus vaccines. PLoS One. 2012;7:e48426.","journal-title":"PLoS One"},{"key":"2592_CR51","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/1471-2458-11-203","volume":"11","author":"VJ Lee","year":"2011","unstructured":"Lee VJ, Tay SK, Teoh YL, Tok MY. Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health. 2011;11:203.","journal-title":"BMC Public Health"},{"key":"2592_CR52","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1258\/ijsa.2007.007113","volume":"19","author":"YP Bao","year":"2008","unstructured":"Bao YP, Li N, Smith JS, Qiao YL. Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis. Int J STD AIDS. 2008;19:106\u201311.","journal-title":"Int J STD AIDS"},{"key":"2592_CR53","first-page":"631","volume":"71","author":"L Mariani","year":"2015","unstructured":"Mariani L, Bonanni P, Castiglia P, Chiamenti G, Conforti G, Conversano M, et al. Prevention of HPV cancer related through HPV-9: state of the art, potential benefits and open issues. Igiene e sanita pubblica. 2015;71:631\u201352.","journal-title":"Igiene e sanita pubblica"},{"key":"2592_CR54","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1056\/NEJMc1504359","volume":"372","author":"U Wieland","year":"2015","unstructured":"Wieland U, Brockmeyer NH, Kreuter A. A 9-Valent HPV Vaccine in Women. N Engl J Med. 2015;372:2566.","journal-title":"N Engl J Med"},{"key":"2592_CR55","first-page":"159","volume":"7","author":"X Liu","year":"2013","unstructured":"Liu X, Feng A, Cui Y, Tobe RG. Prevention of human papillomavirus (HPV) infection and cervical cancer in China: how does HPV vaccination bring about benefits to Chinese women? Biosci Trends. 2013;7:159\u201367.","journal-title":"Biosci Trends"},{"key":"2592_CR56","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/sj.bjc.6604462","volume":"99","author":"M Diaz","year":"2008","unstructured":"Diaz M, Kim JJ, Albero G, Sanjos\u00e9 SD, Clifford G, Bosch FX, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer. 2008;99:230\u20138.","journal-title":"Br J Cancer"},{"key":"2592_CR57","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.vaccine.2010.12.085","volume":"29","author":"K Canfell","year":"2011","unstructured":"Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, et al. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine. 2011;29:2487\u201394.","journal-title":"Vaccine"},{"key":"2592_CR58","doi-asserted-by":"crossref","unstructured":"Zhai L, Tumban E. Gardasil-9: a global survey of projected efficacy. Antivir Res. 2016.","DOI":"10.1016\/j.antiviral.2016.03.016"},{"key":"2592_CR59","unstructured":"ChinaIRN. New opportunities of cervical cancer prevention and control to China in 2014 \n                    http:\/\/www.chinairn.com\/news\/20140506\/124657368.shtml\n                    \n                  . Cited date: 30 Dec 2014."},{"key":"2592_CR60","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12889-016-2873-8","volume":"16","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Wang Y, Liu L, Fan Y, Liu Z, Wang Y, et al. Awareness and knowledge about human papillomavirus vaccination and its acceptance in China: a meta-analysis of 58 observational studies. BMC Public Health. 2016;16:216.","journal-title":"BMC Public Health"},{"key":"2592_CR61","first-page":"620","volume":"63","author":"S Stokley","year":"2014","unstructured":"Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States. MMWR Morb Mortal Wkly Rep. 2014;63:620\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2592_CR62","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jaad.2015.05.041","volume":"73","author":"NS Handler","year":"2015","unstructured":"Handler NS, Handler MZ, Majewski S, Schwartz RA. Human papillomavirus vaccine trials and tribulations: vaccine efficacy. J Am Acad Dermatol. 2015;73:759\u201367. quiz 67-8","journal-title":"J Am Acad Dermatol"},{"key":"2592_CR63","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3201\/eid1402.070499","volume":"14","author":"HW Chesson","year":"2008","unstructured":"Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14:244.","journal-title":"Emerg Infect Dis"},{"key":"2592_CR64","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/0272989X02239651","volume":"23","author":"M Brisson","year":"2003","unstructured":"Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Mak. 2003;23:76\u201382.","journal-title":"Med Decis Mak"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2592-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-017-2592-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2592-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T11:20:20Z","timestamp":1589455220000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2592-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,18]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2592"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2592-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,18]]},"assertion":[{"value":"20 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As there was no direct patient participation in this study, ethic approval was exempted.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final version of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare there were no potential competing interests relevant to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"502"}}